Unlocking the depths: the evolution of robotic-assisted bronchoscopy

Abstract

Robotic-assisted bronchoscopy (RAB) has emerged as a transformative modality in diagnosing peripheral pulmonary lesions, overcoming the limitations of traditional diagnostic techniques.Among the pioneering platforms is the ION™ endoluminal system (ION) by Intuitive Surgical (Sunnyvale, CA, US), which has garnered significant attention for its innovation and clinical impact. This opinion article explores the ION platform's cutting-edge advancements, real-world applications, and prospects, situating it at the forefront of interventional pulmonology.The RAB system leverages shape-sensing robotic-assisted technology to provide unparalleled access and precision in navigating complex bronchial pathways. Previous studies in the Literature have demonstrated how this technology enhances navigation accuracy, particularly in reaching peripheral pulmonary lesions, thereby improving diagnostic yield and clinical outcomes [1,2]. This capability has addressed one of the longstanding challenges in bronchoscopy: reaching small peripheral lesions with high diagnostic yield. Unlike traditional bronchoscopes or previous electromagnetic navigational bronchoscopy (ENB) systems, which rely on pre-procedural computed tomography (CT) scans susceptible to CT-to-body divergence, RAB platforms offer real-time navigation with enhanced stability and control. CT-to-body divergence refers to the discrepancy between the lesion's location in a pre-procedural CT scan and its actual position during bronchoscopy, often due to respiratory motion or anatomical shifts. This phenomenon can reduce the accuracy of navigation systems, particularly those relying solely on static imaging. RAB has improved access to pulmonary parenchymal nodular opacities, allowing for more accurate sampling. This distinction is critical, as not all thoracic nodules are pulmonary in origin. This advancement has improved the feasibility of accessing small peripheral lesions, though challenges remain across different technologies [3,4].A recent multicenter feasibility study in China demonstrated that the ION system can biopsy peripheral pulmonary lesions with a remarkable diagnostic yield of 87.8% [5]. This aligns with findings from a US-based retrospective comparison, where RAB, using the ION platform, achieved an 86.1% diagnostic yield, outperforming ENB's 49.5% yield [2]. The system's ability to access small lesions with high precision underscores its utility in early lung cancer detection, where timely and accurate diagnosis can significantly improve patient outcomes [2,3].The RAB system's advancements are not limited to diagnostic accuracy but extend to patient safety.Traditional techniques such as transthoracic needle aspiration pose risks like pneumothorax and hemorrhage [6,7]. Conversely, the ION platform integrates radial endobronchial ultrasound to confirm lesion localization and employs fine motor control to reduce iatrogenic complications [5].Studies in the Literature report a pneumothorax rate as low as 1.1%, with no cases requiring intervention, highlighting its safety even in high-risk scenarios [1].Additionally, the platform's compatibility with adjunctive imaging modalities, such as cone-beam CT, enhances tool-in-lesion confirmation and procedural success. Cone-beam CT-guided RAB significantly increased the diagnostic yield while maintaining safety standards, particularly by improving the accuracy of lesion targeting during navigation [8]. In addition, cone-beam CT-guided RAB significantly improves sampling accuracy without exceeding safety thresholds for radiation exposure [9]. Such integration is pivotal in minimizing diagnostic errors and ensuring procedural efficacy [10].While the ION system shares the RAB landscape with competitors like the Monarch™ platform (Auris Health, Johnson & Johnson, US), it distinguishes itself through unique technological features (Table 1). The ION system's shape-sensing catheter provides continuous positional